Daniel J. Vis

Daniel J. Vis

Auto-generated profile, based on publicly available information

Daniel J. Vis

Netherlands Cancer Institute

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2016 in Pharmacogenomics
Verified
Journal Article
Closed access
DVDaniel J Vis
Daniel J Vis
LBLorenzo Bombardelli
Lorenzo Bombardelli
HLHoward Lightfoot
Howard Lightfoot
Francesco IorioFrancesco Iorio
Francesco Iorio
MGMathew J Garnett
Mathew J Garnett
LWLodewyk Fa Wessels
Lodewyk Fa Wessels
Aim: Experimental variation in dose–response data of drugs tested on cell lines result in inaccuracies in the estimate of a key drug sensitivity characteristic: the IC50. We aim to improve the precision of the half-limiting dose (IC50) estimates by simultaneously employing all dose–responses across all cell lines and drugs, rather than using a single drug–cell line response. Materials & methods: We propose a multilevel mixed effects model that takes advantage of all available dose–response data. Results: The new estimates are highly concordant with the currently used Bayesian model when the data are well behaved. Otherwise, the multilevel model is clearly superior. Conclusion: The multilevel model yields a significant reduction of extreme IC50 estimates, an increase in precision and it runs orders of magnitude faster.

6 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YKYongsoo Kim
Yongsoo Kim
TBTycho Bismeijer
Tycho Bismeijer
WZWilbert Zwart
Wilbert Zwart
LWLodewyk F. A. Wessels
Lodewyk F. A. Wessels
DVDaniel J. Vis
Daniel J. Vis
Integrative analyses that summarize and link molecular data to treatment sensitivity are crucial to capture the biological complexity which is essential to further precision medicine. We introduce Weighted Orthogonal Nonnegative parallel factor analysis (WON-PARAFAC), a data integration method that identifies sparse and interpretable factors. WON-PARAFAC summarizes the GDSC1000 cell line compendium in 130 factors. We interpret the factors based on their association with recurrent molecular alterations, pathway enrichment, cancer type, and drug-response. Crucially, the cell line derived factors capture the majority of the relevant biological variation in Patient-Derived Xenograft (PDX) models, strongly suggesting our factors capture invariant and generalizable aspects of cancer biology. Furthermore, drug response in cell lines is better and more consistently translated to PDXs using factor-based predictors as compared to raw feature-based predictors. WON-PARAFAC efficiently summarizes and integrates multiway high-dimensional genomic data and enhances translatability of drug response prediction from cell lines to patient-derived xenografts.

29 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSoufiane Mourragui
Soufiane Mourragui
MLMarco Loog
Marco Loog
DVDaniel J. Vis
Daniel J. Vis
KMKat Moore
Kat Moore
AMAnna Gonzalez Manjon
Anna Gonzalez Manjon
LWLodewyk F.A. Wessels
Lodewyk F.A. Wessels
Pre-clinical models have been the workhorse of cancer research for decades. While powerful, these models do not fully recapitulate the complexity of human tumors. Consequently, translating biomarkers of drug response from pre-clinical models to human tumors has been particularly challenging. To explicitly take these differences into account and enable an efficient exploitation of the vast pre-clinical drug response resources, we developed TRANSACT, a novel computational framework for clinical drug response prediction. First, TRANSACT employs non-linear manifold learning to capture biological processes active in pre-clinical models and human tumors. Then, TRANSACT builds predictors on cell line response only and transfers these to Patient-Derived Xenografts (PDXs) and human tumors. TRANSACT outperforms four competing approaches, including Deep Learning approaches, for a set of 15 drugs on PDXs, TCGA cohorts and 226 metastatic tumors from the Hartwig Medical Foundation data. For only four drugs Deep Learning outperforms TRANSACT. We further derived an algorithmic approach to interpret TRANSACT and used it to validate the approach by identifying known biomarkers to targeted therapies and we propose novel putative biomarkers of resistance to Paclitaxel and Gemcitabine.